Products
We offer a wide range of INN and branded generics, specialty products, and consumer healthcare solutions.
At Zentiva, we provide health and wellbeing for all generations by ensuring the supply of high-quality and affordable medicines in Europe and beyond.
Over the years, we have successfully expanded our portfolio through strategic in-licensing and acquisitions, positioning ourselves for continued growth. We aim to support 1 in 5 individuals across Europe.
Retail Generics
Our Retail Generics portfolio sits at the heart of our business, offering a wide range of high-quality, affordable medicines across key therapeutic areas.
We work closely with major wholesalers and independent pharmacy buying groups to ensure broad market access and consistent supply, navigating the dynamic UK generics landscape with agility and precision.
Our wholesale-focused sales force and strategic partnerships enable us to respond swiftly to market shifts, support pricing portals, and maintain strong visibility across national chains and independents.
Hospital Generics and Biosimilars
Our Hospital Generics and Biosimilars portfolio is designed to meet the evolving needs of secondary care providers across the NHS.
We offer a broad and growing range of high-quality, cost-effective medicines across key therapeutic areas including antibiotics, antifungals, anticoagulants, pain management, and oncology. Our biosimilars are developed to match the quality, safety, and efficacy of reference biologics, improving access and affordability for patients and healthcare systems.
Zentiva works closely with national procurement bodies and hospital pharmacy leads to support both tendered and off-contract opportunities, ensuring flexible and competitive pricing strategies.
Branded Generics
Our Branded Generics portfolio is built on delivering high-quality, bioequivalent medicines at the lowest acquisition cost.
We continuously monitor pricing to ensure competitiveness within the UK market. We focus on brand continuity where clinically appropriate, helping healthcare professionals and NHS stakeholders achieve significant prescribing cost efficiencies.
Zentiva UK’s branded generics portfolio is rapidly expanding across multiple therapeutic areas, including:
Mental health
Pain management
Respiratory
Cardiology
Diabetes and metabolism
Value-Added Medicines
Our Value-Added Medicines provide a unique presentation or formulation of an existing molecule
The development of Value-Added Medicines (VAMs) is driven by the need to address specific patient requirements and improve overall healthcare outcomes.
Half doses to eliminate need for tablet splitting
Soluble and liquid forms for patients with swallowing difficulties
Double strength to reduce the pill burden for patients
New strengths for dosage titration
Date of preparation: March 2026 | Ref: 000833019